Daratumumab followed by tocilizumab for treatment of late antibody-mediated rejection in renal transplant recipients with high or moderate levels of de novo donor-specific antibodi... por Zhiliang Guo, Rula Sa, Daqiang Zhao, Songxia Li, Hui Guo, Lan Zhu, Gang Chen

Obter o texto integral